{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,14]],"date-time":"2025-11-14T10:36:05Z","timestamp":1763116565835},"reference-count":33,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2017,11,1]],"date-time":"2017-11-01T00:00:00Z","timestamp":1509494400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","oooojournal.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology"],"published-print":{"date-parts":[[2017,11]]},"DOI":"10.1016\/j.oooo.2017.08.003","type":"journal-article","created":{"date-parts":[[2017,8,18]],"date-time":"2017-08-18T04:01:00Z","timestamp":1503028860000},"page":"e257-e260","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"title":["Axitinib-related osteonecrosis of the jaw"],"prefix":"10.1016","volume":"124","author":[{"given":"Vinod","family":"Patel","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chris","family":"Sproat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jerry","family":"Kwok","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nikki","family":"Tanna","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.oooo.2017.08.003_bib0010","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1038\/sj.bdj.2015.680","article-title":"New cancer therapies and jaw necrosis","volume":"219","author":"Patel","year":"2015","journal-title":"Br Dent J"},{"key":"10.1016\/j.oooo.2017.08.003_bib0015","first-page":"41","article-title":"Sunitinib therapy for meta- static renal cell carcinoma: Recommendations for management of side effects","volume":"1","author":"Kollmannsberger","year":"2007","journal-title":"Can Urol Assoc J"},{"key":"10.1016\/j.oooo.2017.08.003_bib0020","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1016\/j.joms.2014.04.031","article-title":"American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw: 2014 update","volume":"72","author":"Ruggiero","year":"2014","journal-title":"J Oral Maxillofac Surg"},{"key":"10.1016\/j.oooo.2017.08.003_bib0025","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1038\/nrc2152","article-title":"Possible molecular mechanisms involved in the toxicity of angiogenesis inhibition","volume":"7","author":"Verheul","year":"2007","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.oooo.2017.08.003_bib0030","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1124\/jpet.105.084145","article-title":"Role of tyrosine kinase inhibitors in cancer therapy","volume":"315","author":"Arora","year":"2005","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.oooo.2017.08.003_bib0035","author":"Cancer Research UK"},{"key":"10.1016\/j.oooo.2017.08.003_bib0040","doi-asserted-by":"crossref","first-page":"2893","DOI":"10.1002\/ijc.25516","article-title":"Estimates of worldwide burden of cancer in 2008","volume":"27","author":"Ferlay","year":"2010","journal-title":"Int J Cancer"},{"key":"10.1016\/j.oooo.2017.08.003_bib0045","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1016\/j.ejca.2009.12.014","article-title":"Estimates of cancer incidence and mortality in Europe in 2008","volume":"46","author":"Ferlay","year":"2010","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.oooo.2017.08.003_bib0050","author":"Cancer Research UK"},{"key":"10.1016\/j.oooo.2017.08.003_bib0055","doi-asserted-by":"crossref","first-page":"v58","DOI":"10.1093\/annonc\/mdw328","article-title":"Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"27","author":"Escudier","year":"2016","journal-title":"Ann Oncol"},{"key":"10.1016\/j.oooo.2017.08.003_bib0060","doi-asserted-by":"crossref","first-page":"269","DOI":"10.4137\/CMO.S10594","article-title":"Axitinib: a review of its safety and efficacy in the treatment of adults with advanced renal cell carcinoma","volume":"7","author":"Gross-Goupil","year":"2013","journal-title":"Clin Med Insights Oncol"},{"key":"10.1016\/j.oooo.2017.08.003_bib0065","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1016\/S0140-6736(11)61613-9","article-title":"Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial","volume":"378","author":"Rini","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.oooo.2017.08.003_bib0070","author":"National Institute for Health and Care Excellence"},{"key":"10.1016\/j.oooo.2017.08.003_bib0075","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/s12964-016-0129-y","article-title":"Axitinib and sorafenib are potent in tyrosine kinase inhibitor resistant chronic myeloid leukemia cells","volume":"14","author":"Halbach","year":"2016","journal-title":"Cell Commun Signal"},{"key":"10.1016\/j.oooo.2017.08.003_bib0080","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1016\/j.joms.2013.03.019","article-title":"Combination of zoledronic acid and targeted therapy is active but may induce osteonecrosis of the jaw in patients with metastatic renal cell carcinoma","volume":"71","author":"Smidt-Hansen","year":"2013","journal-title":"J Oral Maxillofac Surg"},{"key":"10.1016\/j.oooo.2017.08.003_bib0085","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1002\/jbmr.2693","article-title":"Osteonecrosis of the jaw in the United States Food and Drug Administration's Adverse Event Reporting System (FAERS)","volume":"31","author":"Zhang","year":"2016","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.oooo.2017.08.003_bib0090","doi-asserted-by":"crossref","first-page":"2262","DOI":"10.1210\/endo.137.6.8641174","article-title":"Enhanced expression of vascular endothelial growth factor in human SaOS-2 osteoblast-like cells and murine osteoblasts induced by insulin-like growth factor I","volume":"137","author":"Goad","year":"1996","journal-title":"Endocrinology"},{"key":"10.1016\/j.oooo.2017.08.003_bib0095","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.clgc.2014.12.002","article-title":"Osteonecrosis of the jaw in patients with metastatic renal cell cancer treated with bisphosphonates and targeted agents: results of an Italian multicenter study and review of the literature","volume":"13","author":"Fusco","year":"2015","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.oooo.2017.08.003_bib0100","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1038\/bjc.2012.385","article-title":"Concomitant oral tyrosine kinase inhibitors and bisphosphonates in advanced renal cell carcinoma with bone metastases","volume":"107","author":"Beuselinck","year":"2012","journal-title":"Br J Cancer"},{"key":"10.1016\/j.oooo.2017.08.003_bib0105","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.bone.2013.10.002","article-title":"Clinical study evaluating the effect of bevacizumab on the severity of zoledronic acid-related osteonecrosis of the jaw in cancer patients","volume":"58","author":"Lescaille","year":"2014","journal-title":"Bone"},{"key":"10.1016\/j.oooo.2017.08.003_bib0110","doi-asserted-by":"crossref","first-page":"e2","DOI":"10.1016\/j.oraloncology.2011.07.030","article-title":"A case report of bevacizumab-related osteonecrosis of the jaw: Old problem, new culprit","volume":"48","author":"Di\u015fel","year":"2012","journal-title":"Oral Oncol"},{"key":"10.1016\/j.oooo.2017.08.003_bib0115","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1359\/jbmr.080205","article-title":"Frequency and risk factors associated with osteonecrosis of the jaw in cancer patients treated with intravenous bisphosphonates","volume":"23","author":"Hoff","year":"2008","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.oooo.2017.08.003_bib0120","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1093\/annonc\/mdn653","article-title":"Bevacizumab-associated osteonecrosis of the jaw","volume":"19","author":"Greuter","year":"2008","journal-title":"Ann Oncol"},{"key":"10.1016\/j.oooo.2017.08.003_bib0125","doi-asserted-by":"crossref","first-page":"4037","DOI":"10.1200\/JCO.2007.15.5424","article-title":"Osteonecrosis of the jaw related to bevacizumab","volume":"26","author":"Estilo","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.oooo.2017.08.003_bib0130","doi-asserted-by":"crossref","first-page":"E81","DOI":"10.21037\/jgo.2016.05.07","article-title":"Osteonecrosis of the jaw associated with ziv-aflibercept","volume":"7","author":"Mawardi","year":"2016","journal-title":"J Gastrointest Oncol"},{"key":"10.1016\/j.oooo.2017.08.003_bib0135","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/j.bjoms.2016.11.315","article-title":"Medication-related osteonecrosis of the jaw associated with aflibercept","volume":"55","author":"Zarringhalam","year":"2017","journal-title":"J Oral Maxillofac Surg"},{"key":"10.1016\/j.oooo.2017.08.003_bib0140","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/s10006-010-0224-y","article-title":"Osteonecrosis of the jaw related to sunitinib","volume":"15","author":"Koch","year":"2011","journal-title":"Oral Maxillofac Surg"},{"key":"10.1016\/j.oooo.2017.08.003_bib0145","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.tripleo.2011.06.023","article-title":"Sunitinib related osteonecrosis of jaw: a case report","volume":"113","author":"Fleissig","year":"2012","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol"},{"key":"10.1016\/j.oooo.2017.08.003_bib0150","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.tripleo.2011.08.024","article-title":"Gingival bleeding and jaw bone necrosis in patients with metastatic renal cell carcinoma receiving sunitinib: report of 2 cases with clinical implications","volume":"113","author":"Nicolatou-Galitis","year":"2012","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol"},{"key":"10.1016\/j.oooo.2017.08.003_bib0155","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1111\/adj.12254","article-title":"Osteonecrosis of the jaw in a patient receiving cabozantinib","volume":"60","author":"Marino","year":"2015","journal-title":"Aust Dent J"},{"key":"10.1016\/j.oooo.2017.08.003_bib0160","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.omsc.2017.03.001","article-title":"Osteonecrosis of jaw after antiangiogenic agent administration in a renal cell carcinoma patient","volume":"3","author":"Jung","year":"2017","journal-title":"Oral Maxillofac Surg Cases"},{"key":"10.1016\/j.oooo.2017.08.003_bib0165","doi-asserted-by":"crossref","first-page":"5356","DOI":"10.1200\/JCO.2009.21.9584","article-title":"Longitudinal cohort study of risk factors in cancer patients of bisphosphonate-related osteonecrosis of the jaw","volume":"27","author":"Vahtsevanos","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.oooo.2017.08.003_bib0170","doi-asserted-by":"crossref","first-page":"45","DOI":"10.5624\/isd.2017.47.1.45","article-title":"Risk factors of osteonecrosis of the jaw after tooth extraction in osteoporotic patients on oral bisphosphonates","volume":"47","author":"Jeong","year":"2017","journal-title":"Imaging Sci Dent"}],"container-title":["Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2212440317310179?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2212440317310179?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,8,28]],"date-time":"2018-08-28T13:20:25Z","timestamp":1535462425000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2212440317310179"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,11]]},"references-count":33,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2017,11]]}},"alternative-id":["S2212440317310179"],"URL":"https:\/\/doi.org\/10.1016\/j.oooo.2017.08.003","relation":{},"ISSN":["2212-4403"],"issn-type":[{"value":"2212-4403","type":"print"}],"subject":[],"published":{"date-parts":[[2017,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Axitinib-related osteonecrosis of the jaw","name":"articletitle","label":"Article Title"},{"value":"Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.oooo.2017.08.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}